Skip directly to content

Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance

13/07/20
 
  • Funding to support development of new antibiotics as part of broader industry effort
  • New partnership with more than 20 other companies will focus on medicines that address most resistant bacteria and life-threatening infections
  • Builds on Pfizer’s longstanding work to address the global burden of infectious diseases

 

Pfizer Ltd, Walton Oaks, UK, 09 July 2020 - Pfizer announced today it has pledged US$100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections.

The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organisations to re-invigorate and accelerate antibiotic development.

“As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis,” said Pfizer Chairman and Chief Executive Albert Bourla. “We strongly believe the world cannot tackle the growing threat of AMR without collaboration – and that it will take a combination of prevention measures, responsible stewardship and innovative thinking to overcome existing obstacles. The new AMR Action Fund gives us the vehicle to do that by investing in and stimulating a potentially stronger pipeline for antimicrobial medicines.”

Each year 700,000 people die from AMR. By 2050, it is estimated that AMR could claim as many as 10 million lives per year. To combat AMR, antibiotics should only be used when necessary to preserve their effectiveness.

While antibiotics revolutionised medicine in the 20th century and, together with vaccination, have led to the near eradication of many diseases in the developed world, over time, bacteria change and adapt to the use of antibiotics, rendering them ineffective. This makes it more difficult to treat common infections such as pneumonia, tuberculosis and salmonellosis, leading to longer hospital stays, higher medical costs and increased mortality.

Pfizer takes a multi-pronged approach to tackling AMR. We are a leading developer of vaccines that help prevent infections in the first place, reducing the need for antibiotics that may result in resistant strains. We are also one of the few large research-based pharmaceutical companies still active in research and development for anti-infectives, and work with partners to close critical prevention and treatment gaps in infectious disease around the globe. In addition, we are committed to responsible antibiotic stewardship, and are proud to offer one of the largest and most accessible AMR surveillance programs in the world, called ATLAS – the only platform that provides public access to both antifungal and antibacterial resistance data through a single resource. ATLAS is accessible freely to anyone, anywhere via the Web or the ATLAS mobile application.

Pfizer’s commitment to the AMR Action Fund builds on our long-standing work fighting infectious diseases and reducing health disparities for globally. In partnership with organisations around the world, Pfizer is redefining the way we fight infectious diseases by creating meaningful and sustainable solutions that address today’s biggest health challenges and protect the world’s most vulnerable people.

 

- Ends -

 

About Pfizer: Breakthroughs that change patients’ lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

To learn more, please follow us on TwitterInstagram and like us on Facebook.

 

Contacts

Media Relations Pfizer UK:

Francesca Russo
+44 (0) 7920 548118
francesca.russo@Pfizer.com

 

Related articles:

 

Antibiotics are medicines that work to treat or prevent bacterial infections, but many are losing their effectiveness due to antimicrobial resistance (AMR).

 

Pfizer UK announced an important change to how it incentivises its Anti-Infectives field-force as part of its commitment to the fight against antimicrobial resistance (AMR).

 

For the last 2 years, Pfizer UK has played a key role in the cross-industry initiative to develop a new ‘subscription’ style payment model that aims to encourage pharmaceutical companies to develop new medicines for resistant infections.

PP-PFE-GBR-2773 / July 2020